The company said emricasan, its drug to treat nonalcoholic steatohepatitis, a fatty liver disease, failed to beat a placebo in its midstage clinical trial. It is discontinuing the trial altogether.
In March, the drug failed in a clinical trial with patients with biopsy-confirmed nonalcoholic steatohepatitis and liver fibrosis, and last year it failed to stop or reverse damage to liver transplants caused by hepatitis C.
The company said it is now exploring “strategic alternatives to enhance shareholder value,” including a sale.
The company will also halt development of one of its lead drug candidates for inflammasome disease, CTS-2090.
More articles on pharmacy:
Lupin recalls 18,408 bottles of antibiotic in US
Bluebird Bio prices gene therapy at $1.8M
10 hospitals seeking pharmacy leaders
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
